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Abstract
Background:  Although  photocoagulation  reduces  the  incidence  of  moderate  visual  loss  in  eyes
with focal  diabetic  macular  oedema,  some  eyes  may  lose  some  vision  after  treatment.  The
proportion  of  eyes  with  poor  functional  response  after  photocoagulation,  and  whether  any
retinal variable  is  associated  with  this,  is  unknown.
Objective:  To  determine  the  proportion  of  eyes  with  diabetic  macular  oedema  that  have  a  poor
functional  response  after  focal  photocoagulation,  and  their  associated  features.
Material  and  methods:  A  non-experimental,  longitudinal,  comparative  and  retrospective  study
was conducted.  The  proportion  and  95%  conﬁdence  intervals  (CI)  of  diabetics  with  macular
oedema that  had  a  poor  functional  response  after  focal  photocoagulation  (any  visual  loss
after 6  weeks)  were  identiﬁed.  The  means  of  retinal  variables  before  treatment  were  com-
pared between  eyes  with  and  without  a  poor  functional  response  using  the  Student  t  test  for
independent  means.
Results:  The  study  included  115  eyes  of  patients  aged  59.3  (SD  9.24)  years.  Visual  acuity  was
greater than  or  equal  to  0.5  in  63  eyes  (54.8%).  A  total  of  33  eyes  had  a  poor  functional  response
after photocoagulation  (28.7%,  95%  CI:  13.3--44.1).  The  comparison  between  retinal  variables
and visual  acuity  before  treatment  did  not  show  any  differences  between  eyes  with  or  without
a poor  functional  response  and  eyes  (p  >  0.05).
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Conclusion:  Retinal  thickening  and  visual  acuity  improved  or  did  not  change  in  71.3%  of  eyes
with diabetic  macular  oedema  with  a  single  photocoagulation  procedure.  Retinal  variables  that
are usually  evaluated  were  unable  to  identify  the  remaining  28.7%,  which  could  lose  vision  after
that treatment,  and  would  require  additional  interventions.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Falta  de  asociación  entre  las  características  retinianas  previas  al  tratamiento  y  la
mala  respuesta  funcional  a  la  fotocoagulación  focal,  en  edema  macular  diabético
Resumen
Antecedentes:  La  fotocoagulación  reduce  la  incidencia  de  pérdida  visual  moderada  en  ojos
con edema  macular  diabético  focal,  aunque  en  algunos  disminuye  la  visión.  Se  desconoce  la
proporción  de  ojos  que  presenta  mala  respuesta  funcional  después  de  la  fotocoagulación  y  si
esta se  asocia  con  alguna  característica  retiniana  previa.
Objetivo:  Determinar  la  proporción  de  ojos  con  edema  macular  diabético  que  presenta  mala
respuesta funcional  a  la  fotocoagulación  y,  comparar  las  características  retinianas  entre  ojos
con y  sin  ella.
Material  y  métodos: Estudio  observacional,  longitudinal,  comparativo,  retrospectivo.  Se  iden-
tiﬁcó la  proporción  e  intervalos  de  conﬁanza  (I.C.)  del  95%  de  ojos  con  edema  macular  diabético
focal, que  tuvo  mala  respuesta  funcional  después  de  la  fotocoagulación  (disminución  de  agudeza
visual 6  semanas  después).  Se  compararon  las  variables  retinianas  previas  al  tratamiento,  entre
ojos con  y  sin  mala  respuesta  funcional  (t  de  Student).
Resultados:  Se  trabajó  sobre  115  ojos  de  pacientes  con  edad  promedio  59.3  ±  9.24  an˜os.  La
agudeza visual  era  ≥  0.5  en  63  (54.8%);  33  ojos  tuvieron  mala  respuesta  funcional  después  de
la fotocoagulación  (28.7%,  I.C.  95%:  13.3  a  44.1).  Las  variables  retinianas  no  diﬁrieron  entre  los
ojos con  mala  respuesta  funcional  y  los  ojos  sin  ella  (p  >  0.05).
Conclusión:  En  71.3%  de  los  ojos  con  edema  macular  diabético  focal,  el  engrosamiento  retiniano
remitió y  la  agudeza  visual  se  conservó  o  mejoró  con  un  solo  procedimiento  de  fotocoagulación;
las variables  retinianas  evaluadas  habitualmente  no  permitieron  identiﬁcar  al  28.7%  restante,
cuya visión  puede  disminuir  después  de  este  tratamiento,  y  que  requeriría  intervenciones  adi-
cionales.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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iabetic  retinopathy  is  the  main  cause  of  blindness  in  peo-
le  of  working  age  in  the  world;  it  threatens  vision  in  two
ays;  proliferative  retinopathy  and  macular  oedema.1 The
atter  is  the  most  common  cause  of  sight  loss  in  diabetics
ith  retinopathy,  and  consists  of  the  enlargement  of  the
etina  in  the  area  of  best  sight,  due  to  abnormal  capillary
ermeability.2
Six  percent  of  diabetics  develop  clinically  signiﬁcant
acular  oedema,1 which  can  cause  moderate  sight  loss:  a
hree-line  reduction  on  the  sight  chart,  which  affects  33%  of
ntreated  cases.3 The  Early  Treatment  Diabetic  Retinopathy
tudy  [ETDRS])  demonstrated  the  efﬁcacy  of  photocoagula-
ion  in  reducing  this  outcome  to  13%.4Although  photocoagulation  reduces  the  incidence  of
oderate  sight  loss,  in  a  few  cases  it  improves  vision;
isual  gain  is  less  frequent  if  the  capillary  ﬁltration  on  a
etinal  angiography  is  diffuse.5 When  this  condition  exists,
i
f
andothelial  vascular  growth  factor  (EVGF)  blockers  via  the
ntra-vitreous  route  are  more  effective  than  photocoagula-
ion  in  reducing  retinal  thickness  and  improving  vision6;  this
reatment  requires  from  3  to  5  injections  at  intervals  of  one
onth.7,8
EVGF  blockers  have  been  evaluated  as  limited  in  eyes
ith  clinically  signiﬁcant  macular  oedema  and  visual  acu-
ty  >  20/30,  and  for  these  cases  photocoagulation  is  the  ther-
py  of  choice9; most  of  these  eyes  have  focal  ﬁltration,  and
heir  oedema  regresses  after  one  single  photocoagulation
ession;  this  is  an  advantage  of  this  treatment  over  others.
ven  when  macular  oedema  subsides,  eyes  treated  with  pho-
ocoagulation  can  lose  one  or  2  lines  of  vision;  this  sight  loss
s  not  ‘‘moderate’’,  but  would  represent  a  poor  functional
esponse  to  photocoagulation,  if  one  considers  that  vision
mproves  in  most  eyes  treated  with  EVGF  blockers.
The  proportion  of  eyes  with  focal  oedema  with  a  poor
unctional  response,  and  its  associated  characteristics  after
 single  photocoagulation  session,  is  unknown.  Objective
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rLack  of  correlation  between  retinal  variables  
measurement  of  the  retina  which  is  provided  by  optical
coherence  tomography  might  identify  associations  between
poor  functional  response  and  photocoagulation,  and  alter-
ations  in  variables  measured  by  the  rapid  macular  mapping
test,  such  as  central  point  thickness  (thickness  at  the  inter-
section  of  6  radial  scans  of  6  mm  which  cross  the  centre  of
the  macula),  the  thickness  of  the  central  ﬁeld  (average  reti-
nal  thickness  in  a  circle  with  a  1  mm  diameter,  concentric  to
the  centre  of  the  macula)  or  the  macular  volume.10
A  study  was  performed  to  determine  the  proportion  of
eyes  with  clinically  signiﬁcant  macular  oedema  which  pre-
sented  a  poor  functional  response,  6  weeks  after  focal
photocoagulation,  and  the  association  of  this  outcome  with
the  characteristics  prior  to  the  procedure.
Materials and methods
An  observational,  longitudinal,  comparative  and  retrospec-
tive  study  was  performed.  The  target  population  was  type  2
diabetics  of  the  Distrito  Federal  and  its  metropolitan  area;
the  accessible  population  was  diabetics  attended  in  a  gen-
eral  hospital  between  1  January  2012  and  30  June  2014.  The
study  took  place  from  1  September  to  30  November  of  2014,
in  compliance  with  the  principles  of  the  Helsinki  Declara-
tion  and  was  approved  by  the  Research  and  Research  Ethics
Committees  of  the  hospital  where  it  was  undertaken.
Type  2  diabetic  patients  aged  between  35  and  80  were
included  in  the  study,  with  any  grade  of  diabetic  retinopathy,
and  clinically  signiﬁcant  macular  oedema  with  focal  ﬁltra-
tion  on  retinal  ﬂuoroangiography,  and  spongiform  pattern
on  optical  coherence  tomography,  who  had  been  treated
with  focal  photocoagulation  recorded  with  best-corrected
visual  acuity,  and  with  optical  coherence  tomography  mac-
ular  mapping  of  6  mm,  on  the  day  of  treatment  and  6  weeks
afterwards,  in  whom  the  retinal  swelling  had  resolved.  Eyes
which  had  developed  any  other  eye  disease  which  reduced
best-corrected  visual  acuity,  those  presenting  an  increased
foveal  vascular  area  on  retinal  ﬂuoroangiography,  and  those
whose  rapid  macular  mapping  had  measurement  errors  were
excluded  from  the  study.
Visual  acuity  under  subjective  refraction  in  decimal
equivalent  was  measured  in  all  the  patients.  The  proportion
of  eyes  was  identiﬁed  whose  best-corrected  visual  acuity
was  <  0.5  before  treatment,  as  this  is  the  cut-off  point  used
by  the  ETDRS  to  qualify  poor  visual  acuity,  and  the  degree
of  diabetic  retinopathy  was  determine  in  each  treated  eye,
according  to  the  classiﬁcation  of  the  American  Academy  of
Ophthalmology.
Retinal  thickness  was  measured  by  means  of  the  rapid
macular  mapping  test  of  6  mm,  of  Stratus  (Carl  Zeiss
Meditec,  Inc,  Dublin,  CA,  U.S.A.,  software  version  4.01)
optical  coherence  tomography  equipment,  under  the  fol-
lowing  standard  procedure:  mydriasis  ≥  6mm,  scan  for  dark
eyes,  identiﬁcation  of  the  plane  of  the  retina  by  acoustic
alarm,  and  optimisation  of  the  Z-axis  and  polarisation.  All
the  images  were  obtained  with  ﬂash  between  09.00  and
11.00  am.The  central  point  thickness  was  measured  in  all  the  eyes
and  the  central  ﬁeld  thickness  in  m,  and  macular  volume
in  mm3.  The  measurements  were  taken  automatically  by
the  optical  coherence  tomography  equipment.  Any  deviation
l
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m
p5
f  the  optical  coherence  tomography  line  with  respect  to
he  real  limit  of  the  retina  was  considered  a  measurement
rror,  at  a  standard  deviation  ratio  of  central  point  thick-
ess/central  point  thickness  >  0.111 and  a  signal  intensity
f  <  4.
The  variable  under  study  was  the  poor  functional
esponse  after  photocoagulation,  deﬁned  operationally  as
ny  reduction  in  best-corrected  visual  acuity  6  weeks  after
he  procedure,  compared  to  that  recorded  before  it.  Pre-
ictive  variables  were  considered  at  best-corrected  visual
cuity  <  0.5,  at  central  ﬁeld  thickness,  and  at  the  mac-
lar  volume  prior  to  treatment;  the  proportion  of  eyes
ith  central  thickening  was  identiﬁed,  operationally  iden-
iﬁed  as  thickness  of  the  central  ﬁeld  >  212.5  m,  which
epresents  a  value  2  standard  deviations  above  the  aver-
ge  reported  in  diabetic  patients  without  oedema  in  our
opulation  (188.7  m).12
The  proportion  and  95%  conﬁdence  intervals  (CI)  were
dentiﬁed  of  eyes  with  a  poor  functional  response  after  pho-
ocoagulation;  the  central  point  thickness  averages,  central
eld  thickness,  macular  volume  and  best-corrected  visual
cuity  in  decimal  equivalent,  were  compared  between  the
yes  with  poor  functional  response  after  photocoagulation
nd  the  remainder,  by  means  of  Student’s  t-test  for  indepen-
ent  measurements.  The  central  point  thickness  averages,
entral  point  thickness,  and  macular  volume  before  and
fter  the  treatment  were  compared  in  each  group  by  means
f  a  Student’s  t-test  for  paired  samples.
The  proportion  of  cases  with  poor  functional  response
fter  photocoagulation  was  compared  with  the  eyes  with  a
revious  visual  acuity  of  <  0.5,  and  the  eyes  with  a  previ-
us  visual  acuity  of  ≥  0.5,  and  between  the  eyes  with  and
ithout  central  thickening,  by  means  of  the  2 test.  The
roportion  and  95%  conﬁdence  intervals  (CI)  of  eyes  which
resented  moderate  sight  loss  6  months  after  treatment
ere  also  identiﬁed;  the  information  was  stored  and  ana-
ysed  using  SPSS  for  Windows  version  22;  a  p  value  of  <  0.05
as  considered  statistically  signiﬁcant.
esults
15  eyes  were  assessed,  of  58  patients,  aged  from  35  to
7  (average  age  59.3,  standard  deviation  [S.D.]  ±  9.24);  49
f  the  eyes  were  those  of  females  (42.6%);  the  patients
ad  a  history  of  diabetes  from  1  to  30  years  (average
5.15,  S.D.  ±  7.14),  37  eyes  were  those  of  patients  treated
ith  insulin  (32.2%).  The  average  of  random  capillary  glu-
ose  was  167.25  mg/dl  (S.D.  ±  70.93)  and  that  of  glycated
aemoglobin  was  9.15%  (S.D.  ±  2.56),  62  eyes  were  those  of
atients  with  systemic  arterial  hypertension  (53.9%).
Best-corrected  visual  acuity  before  photocoagulation  had
 distance  of  0.06  to  1  (average  0.56,  S.D.  ±  0.29);  it  was
 0.5  in  63  eyes  (54.8%)  and  <  0.5  in  52  (45.2%);  13  patients
resented  mild  non-proliferating  retinopathy  (11.3%),  63
oderate  non-proliferating  retinopathy  (54.8%),  6  severe
on-proliferating  retinopathy  (5.2%),  and  33  proliferating
etinopathy  (28.7%).
The  average  central  point  thickness  before  photocoagu-
ation  was  182.26  m  (S.D.  ±  47.53  m),  the  average  central
eld  thickness  215.16  m  (S.D.  ±  42.07  m)  and  average
acular  volume  7.76  mm3 (S.D.  ±  0.87  mm3).  Six  weeks  after
hotocoagulation  the  average  central  point  thickness  was
6  Y.  Ávila-Alcaraz  et  al.
Table  1  Comparison  of  the  variables  prior  to  treatment,  between  eyes  with  poor  functional  response  to  photocoagulation  and
eyes with  good  functional  response.
Variables  Poor  functional  response  after
photocoagulation  (n  =  33)
Remaining  eyes
(n  =  82)
p
Age  60.5  ±  8.6  58.8  ±  9.4  0.4a
Time  since  onset  of  diabetes  (years)  14.3  ±  7.4  15.5  ±  7.0  0.4a
Fasting  blood  sugar  (mg/dl)  168.6  ±  80.3  166.8  ±  68.4  0.9a
Initial  best-corrected  visual  acuity  (decimal  equivalent)  0.62  ±  0.31  0.53  ±  0.28  0.1a
CFT  (m) 192.4  ±  67.7  178.2  ±  36.2  0.2a
CPT  (m) 224.8  ±  58.5 211.3  ±  32.9  0.2a
Macular  volume  (mm3) 7.84  ±  1.1 7.72  ±  0.78 0.5a
Female  gender  (%) 42.4 42.7 0.9b
Treatment  with  insulin  (%)  33.3  31.7  0.8b
Arterial  hypertension  (%)  63.6  48.8  0.2b
Best-corrected  visual  acuity  <  0.5%  39.4  47.6  0.4b
Proliferating  retinopathy  (%)  27.3  29.3  1.0b
Central  thickening  (%)  45.4  40.2  0.6b
CFT, central ﬁeld thickness; CPT, central point thickness.
a Student’s t-test for independent means.
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82.05  ±  43.33  m  (p  =  0.9),  the  average  central  ﬁeld  thick-
ess  214.59  ±  38.83  m  (p  =  0.8)  and  the  average  macular
olume  7.63  ±  0.77  mm3 (p  <  0.001).
After  photocoagulation,  visual  acuity  had  a  distance  of
.03--1.00  (average  0.60  ±  0.29,  p  =  0.16);  it  improved  in  51
yes  (44.3%),  did  not  change  in  31  (26.9%)  and  reduced  in
3  (28.7%).  Three  eyes  presented  moderate  sight  loss  (2.6%,
.I.  95%:  0--5.5%)  and  33  had  poor  functional  response  after
hotocoagulation  (28.7%,  95%  CI:  20.4--37.0).
In  the  eyes  with  poor  functional  response  after  photoco-
gulation,  the  average  central  point  thickness  changed  from
92.45  ±  67.7  m  before  the  treatment  to  187.64  ±  57.9  m
fter  it  (p  =  0.5);  the  average  central  ﬁeld  thickness  changed
rom  224.8  ±  58.5  m  to  219.6  ±  50.8  m  (p  =  0.4)  and  the
verage  macular  volume  changed  from  7.84  ±  1.06  to
.61  ±  0.81  mm3 (p  =  0.01).  In  the  remaining  eyes  the  cen-
ral  point  thickness  average  changed  from  178.2  ±  36.2  m
o  179.8  ±  36.04  m  (p  =  0.6);  the  average  central  ﬁeld
hickness  changed  from  211.3  ±  32.9  m  to  212.6  ±  32.9  m
p  = 0.6)  and  the  average  macular  volume  changed  from
.73  ±  0.78  to  7.64  ±  0.76  mm3 (p  =  0.01).The  comparison  of  the  ocular  and  systemic  variables
efore  photocoagulation,  between  the  eyes  that  presented
oor  functional  response  and  the  remainder,  is  shown  in
able  1;  no  signiﬁcant  differences  were  found  which  enabled
s
a
t
Table  2  Comparison  of  the  proportion  of  cases  with  poor  function
acuity <  0.5  and  eyes  with  visual  acuity  ≥  0.5  before  treatment.
Visual  acuity  Poor  functional  response  to
photocoagulation  (n  =  33),  n  (%)
<  0.5 13  (25)  
≥ 0.5 20  (31.7)
Total 33  (28.7)  
a 2.ny  variable  prior  to  the  treatment  to  be  associated  with
oor  functional  response  after  photocoagulation.
There  was  no  signiﬁcant  difference  between  the  eyes
ith  a  poor  response  after  photocoagulation,  and  the  eyes
ithout  it,  compared  to  the  absolute  averages  of  change  in
entral  point  thickness  (−4.8  ±  44.1  m  vs  1.6  ±  30.1  m),  in
entral  ﬁeld  thickness  (−5.1  ±  35  m  vs  1.3  ±  24.0  m)  and
n  macular  volume  (−0.23  ±  0.47  mm3 vs  −0.08  ±  0.29  mm3).
The  proportion  of  cases  with  poor  functional  response
o  photocoagulation  did  not  differ  between  the  eyes  with
isual  capacity  of  <  0.5,  and  the  eyes  with  visual  acuity  ≥  0.5
Table  2);  neither  did  it  differ  between  the  eyes  with  and
ithout  thickening  in  the  centre  of  the  macula  (Table  3).
iscussion
n  28.7%  of  the  eyes  with  macular  oedema  treated  with
ocal  photocoagulation  visual  acuity  decreased,  even  when
he  retinal  thickening  resolved;  in  the  remaining  71.3%,  the
reatment  was  efﬁcient  in  preventing  sight  loss,  with  one
ingle  procedure.
The  operational  deﬁnition  of  poor  functional  response
fter  photocoagulation  in  this  study  did  not  correspond  to
he  outcome  that  one  wishes  to  avoid  in  patients  with
al  response  after  photocoagulation,  between  eyes  with  visual
Remaining  eyes
(n =  82),  n  (%)
pa
39  (75)  0.4
43  (68.3)
82  (71.3)
Lack  of  correlation  between  retinal  variables  7
Table  3  Comparison  of  the  proportion  of  cases  with  poor  functional  response  after  photocoagulation,  between  eyes  with  and
without thickening  of  the  centre  of  the  fovea  before  treatment.
Thickening  of  the  centre
of the  macula
Poor  functional  response  to
photocoagulation  (n  =  33),  n  (%)
Remaining  eyes
(n  =  82),  n  (%)
pa
Present  18  (26.9)  49  (73.1)  0.4
Absent 15  (31.3)  33  (28.7)
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CTotal 33  (28.7)  
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clinically  signiﬁcant  macular  oedema:  moderate  sight  loss.
Only  2.65%  of  the  eyes  in  the  sample  presented  this  out-
come,  compared  to  the  13%  reported  by  the  ETDRS.  Although
the  results  at  6  weeks  did  not  represent  the  outcome  at  3
years,  it  should  be  considered  that  the  proportion  of  mod-
erate  sight  loss  at  6  weeks  in  the  ETDRS  was  greater  in  the
treated  eyes  than  in  the  untreated  eyes.4
The  poor  functional  response  after  photocoagulation  did
not  correspond  to  a  therapeutic  failure,  a  deﬁnition  that
refers  to  the  persistence  of  retinal  thickening  4  months  after
the  procedure.  In  the  sample,  thickening  reduced  signiﬁ-
cantly  both  in  the  eyes  with  poor  functional  response  after
photocoagulation,  and  in  the  remaining  eyes.
In  this  study,  any  decrease  in  visual  acuity  was  deﬁned  as
a  poor  functional  response  after  photocoagulation,  because
there  are  efﬁcient  therapies  to  improve  vision  for  eyes  with
diffuse  oedema.13--15 In  eyes  with  focal  macular  oedema  not
only  should  we  try  to  prevent  the  loss  of  3  lines  of  vision,
but  any  reduction  in  visual  acuity.
Unlike  photocoagulation,  therapies  with  glucocorticoids
or  EVGF  antagonists  have  a  transitory  effect,  and  therefore
various  procedures  are  required  to  achieve  the  thera-
peutic  goal.  However,  they  are  currently  indicated  for
treating  diffuse  oedema  (in  combination  or  otherwise  with
photocoagulation)16 because  their  effect  on  vision  is  better
than  that  of  isolated  photocoagulation.
In  focal  macular  oedema  general  sight  loss  and  retinal
thickening  are  of  greater  magnitude  than  in  diffuse  macular
oedema;  therefore,  focal  photocoagulation  remains  effec-
tive  in  preventing  moderate  sight  loss.  Photocoagulation
treats  isolated  sites  of  capillary  leakage,  and  causes  less
inﬂammation  than  that  caused  by  60--100  spots  of  grid  laser
treatment  for  diffuse  oedema.  However,  eyes  with  focal
oedema  whose  vision  has  reduced  by  at  least  one  line  after
photocoagulation  might  require  other  treatment.
The  variables  that  have  traditionally  been  evaluated  as
predictive  of  a  response  to  photocoagulation  are  visual  acu-
ity  <  0.5,  and  the  central  location  of  macular  oedema;  these
variables  did  not  modify  the  proportion  of  eyes  with  poor
functional  response  after  photocoagulation,  according  to
the  operational  deﬁnition.  Neither  did  the  other  anatom-
ical  variables  measured  by  optical  coherence  tomography,
one  of  the  principal  tools  for  guiding  treatment  of  macu-
lar  oedema,  the  correlation  of  which  with  visual  acuity  is
slight.17
Strict  control  of  glycaemia  reduces  the  incidence  of  dia-
betic  retinopathy,  but  the  extent  to  which  it  contributes
towards  the  visual  result  6  weeks  after  photocoagula-
tion  is  not  known  in  eyes  with  focal  macular  oedema.
Recent  studies  evaluating  its  participation  in  the  response  to
R
i
e
f82  (71.3)
herapy  with  VEGF  blockers  have  encountered  differences
n  anatomical  outcome,  but  not  in  functional  outcome,18
nd  have  identiﬁed  that  insulin  therapy  compared  to  oral
lucose-lowering  drugs  does  not  change  the  efﬁcacy  of  the
reatment.19
Other  functional  variables  might  modify  the  response
o  treatment,  such  as  retinal  sensitivity,  a  form  of  esti-
ating  the  overall  function  of  the  macula  which  can  be
easured  with  conventional  perimetry  or  micro-perimetry.
n  patients  with  macular  oedema  a  reduction  in  sensitiv-
ty  has  been  reported  even  in  eyes  with  slightly  increased
etinal  thickness,20,21 Which  might  explain  the  variability  of
esponse  to  photocoagulation  and  require  speciﬁc  evalua-
ion.
It  would  also  be  useful  to  speciﬁcally  evaluate  the  condi-
ion  of  the  temporal  perifoveal  sector  which,  if  it  does  not
resent  thickening,  has  been  associated  with  a  greater  inci-
ence  of  visual  improvement  after  focal  photocoagulation.22
nother  variable  which  might  participate  would  be  the
ondition  of  the  perifoveal  capillary  network.  Although  none
f  the  eyes  in  the  sample  had  characteristics  of  macular
schaemia,  the  condition  of  the  perifoveal  capillaries  might
ave  differences  associated  with  poor  functional  response
fter  photocoagulation.
At  this  time  there  is  no  available  data  which  enables
atients  to  be  identiﬁed  with  clinically  signiﬁcant  focal  mac-
lar  oedema  who  might  present  a  poor  functional  response
fter  photocoagulation.  In  order  to  propose  an  adjunct  ther-
py  with  the  procedure,  variables  other  than  the  traditional
eed  to  be  identiﬁed,  which  are  signiﬁcantly  associated  with
oor  functional  response,  and  which  can  be  changed;  other-
ise,  there  is  the  risk  of  giving  unnecessary  treatments  to
eople  whose  response  is  adequate.
Transitory  sight  loss  associated  with  photocoagulation
s  caused  by  inﬂammation,  and  adjunt  therapy  with  non-
teroidal  anti-inﬂammatory  drugs  results  in  more  eyes  with
isual  improvement.23 It  is  not  known  whether  this  treat-
ent  is  also  effective  in  reducing  the  amount  of  cases  with
oor  functional  response,  and  therapy  should  be  assessed
rospectively,  as  should  other  variables  which  might  be  asso-
iated  with  a  reduction  in  visual  acuity,  although  not  falling
nder  the  deﬁnition  of  moderate  sight  loss.
onclusionetinal  variables  prior  to  treatment,  evaluated  traditionally
n  eyes  with  diabetic  macular  oedema,  did  not  show  differ-
nces  between  the  eyes  with  poor  functional  response  after
ocal  photocoagulation  and  the  eyes  without  this  outcome.
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